Larissa Wenning

3.9k total citations
71 papers, 2.9k citations indexed

About

Larissa Wenning is a scholar working on Infectious Diseases, Virology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Larissa Wenning has authored 71 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 22 papers in Virology and 19 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Larissa Wenning's work include HIV/AIDS drug development and treatment (34 papers), HIV Research and Treatment (22 papers) and Pharmacological Effects and Toxicity Studies (11 papers). Larissa Wenning is often cited by papers focused on HIV/AIDS drug development and treatment (34 papers), HIV Research and Treatment (22 papers) and Pharmacological Effects and Toxicity Studies (11 papers). Larissa Wenning collaborates with scholars based in United States, Switzerland and China. Larissa Wenning's co-authors include Marian Iwamoto, William M. Miller, Dominic C. Chow, John A. Wagner, Julie A. Stone, Eleftherios T. Papoutsakis, Bach‐Yen Nguyen, Hedy Teppler, Eleftherios T. Papoutsakis and Robin Isaacs and has published in prestigious journals such as Analytical Chemistry, Clinical Infectious Diseases and Biophysical Journal.

In The Last Decade

Larissa Wenning

71 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Larissa Wenning United States	27	1.9k	1.3k	560	448	381	71	2.9k
Marian Iwamoto United States	32	1.7k 0.9×	1.1k 0.8×	681 1.2×	531 1.2×	399 1.0×	111	2.9k
Jean‐Pierre Sommadossi United States	35	2.0k 1.0×	1.0k 0.8×	1.0k 1.8×	1.2k 2.7×	302 0.8×	98	3.8k
Joseph M. Custodio United States	18	1.4k 0.7×	874 0.7×	247 0.4×	234 0.5×	207 0.5×	40	2.0k
Gabriel Birkuš United States	23	1.2k 0.6×	626 0.5×	572 1.0×	577 1.3×	119 0.3×	41	1.9k
Margalida Rotger Switzerland	23	1.1k 0.6×	849 0.7×	245 0.4×	266 0.6×	279 0.7×	40	1.9k
Polina German United States	20	905 0.5×	272 0.2×	377 0.7×	425 0.9×	202 0.5×	36	1.9k
K. Tsuchiya Japan	23	805 0.4×	523 0.4×	254 0.5×	229 0.5×	131 0.3×	76	1.6k
Margo Heath‐Chiozzi United States	13	852 0.5×	801 0.6×	175 0.3×	265 0.6×	81 0.2×	22	1.7k
Rui M. M. Victorino Portugal	25	422 0.2×	1.1k 0.8×	203 0.4×	544 1.2×	72 0.2×	102	2.6k
N J Fitch United Kingdom	9	691 0.4×	874 0.7×	269 0.5×	320 0.7×	188 0.5×	14	2.1k

Countries citing papers authored by Larissa Wenning

Since Specialization

Citations

This map shows the geographic impact of Larissa Wenning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larissa Wenning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larissa Wenning more than expected).

Fields of papers citing papers by Larissa Wenning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larissa Wenning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larissa Wenning. The network helps show where Larissa Wenning may publish in the future.

Co-authorship network of co-authors of Larissa Wenning

This figure shows the co-authorship network connecting the top 25 collaborators of Larissa Wenning. A scholar is included among the top collaborators of Larissa Wenning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larissa Wenning. Larissa Wenning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hu, Ziheng, et al.. (2024). Population pharmacokinetic modeling of sotatercept in healthy participants and patients with pulmonary arterial hypertension. CPT Pharmacometrics & Systems Pharmacology. 13(8). 1380–1393. 2 indexed citations

Kerbusch, Thomas, et al.. (2020). Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials. British Journal of Clinical Pharmacology. 86(9). 1795–1806. 5 indexed citations

Khalilieh, Sauzanne, Ka Lai Yee, Rosa I. Sánchez, et al.. (2020). Clinical Pharmacokinetics of the Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor Doravirine: An Assessment of the Effect of Patient Characteristics and Drug–Drug Interactions. Clinical Drug Investigation. 40(10). 927–946. 17 indexed citations

Yee, Ka Lai, Tamara D. Cabalu, Yuhsin Kuo, et al.. (2020). Physiologically Based Pharmacokinetic Modeling of Doravirine and Its Major Metabolite to Support Dose Adjustment With Rifabutin. The Journal of Clinical Pharmacology. 61(3). 394–405. 5 indexed citations

Marshall, William L., Larissa Wenning, Xiaobi Huang, et al.. (2017). Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic Impairment. European Journal of Drug Metabolism and Pharmacokinetics. 43(3). 321–329. 4 indexed citations

Rizk, Matthew L., Lihong Du, Larissa Wenning, et al.. (2015). Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV‐infected children 4 weeks to 18 years of age. The Journal of Clinical Pharmacology. 55(7). 748–756. 13 indexed citations

Khalilieh, Sauzanne, Hwa-ping Feng, Ellen G. J. Hulskotte, Larissa Wenning, & Joan R. Butterton. (2015). Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions. Clinical Pharmacokinetics. 54(6). 599–614. 6 indexed citations

Sulkowski, Mark, Stanislas Pol, Josep Mallolas, et al.. (2013). Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. The Lancet Infectious Diseases. 13(7). 597–605. 142 indexed citations

Squires, Kathleen, Linda‐Gail Bekker, Joseph J. Eron, et al.. (2013). Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study. AIDS Research and Human Retroviruses. 29(6). 859–870. 16 indexed citations

10.

Nguyen, Bach‐Yen, Robin Isaacs, Hedy Teppler, et al.. (2011). Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium. Annals of the New York Academy of Sciences. 1222(1). 83–89. 41 indexed citations

11.

Brainard, Diana M., Evan Friedman, Bo Jin, et al.. (2010). Effect of Low-, Moderate-, and High-Fat Meals on Raltegravir Pharmacokinetics. The Journal of Clinical Pharmacology. 51(3). 422–427. 44 indexed citations

12.

Anderson, Matt S., William D. Hanley, Bo Jin, et al.. (2010). Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. British Journal of Clinical Pharmacology. 71(4). 616–620. 18 indexed citations

13.

Iwamoto, Marian, William D. Hanley, Amelia S. Petry, et al.. (2009). Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics. Antimicrobial Agents and Chemotherapy. 53(5). 1747–1752. 37 indexed citations

14.

Hanley, William D., Larissa Wenning, James Kost, et al.. (2009). Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir. Antimicrobial Agents and Chemotherapy. 53(7). 2752–2755. 35 indexed citations

15.

Wenning, Larissa. (2008). Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV-Infected Patients Following 48 Weeks of Treatment. 46th Annual Meeting. 8 indexed citations

16.

Iwamoto, Marian, Larissa Wenning, Sheila Breidinger, et al.. (2008). Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval. The Journal of Clinical Pharmacology. 48(6). 726–733. 39 indexed citations

17.

Karanam, Bindhu V., Maria Madeira, Scott A. Bradley, et al.. (2007). Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans. Drug Metabolism and Disposition. 35(7). 1196–1202. 24 indexed citations

18.

Kassahun, Kelem, Ian McIntosh, Donghui Cui, et al.. (2007). Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme. Drug Metabolism and Disposition. 35(9). 1657–1663. 223 indexed citations

19.

Chow, Dominic C., Larissa Wenning, William M. Miller, & Eleftherios T. Papoutsakis. (2001). Modeling pO2 Distributions in the Bone Marrow Hematopoietic Compartment. II. Modified Kroghian Models. Biophysical Journal. 81(2). 685–696. 246 indexed citations

20.

Chow, Dominic C., Larissa Wenning, William M. Miller, & Eleftherios T. Papoutsakis. (2001). Modeling pO2 Distributions in the Bone Marrow Hematopoietic Compartment. I. Krogh's Model. Biophysical Journal. 81(2). 675–684. 202 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact